{"id":"W4408758370","doi":"10.21203/rs.3.rs-6185818/v1","title":"Maveropepimut-S, Pembrolizumab and Low-dose Cyclophosphamide in Patients with Metastatic Ovarian Cancer: Final Results from Phase 1/2 PESCO trial","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cyclophosphamide; Oncology; Internal medicine; Ovarian cancer; Phase (matter); Cancer; Chemotherapy; Physics; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192659,0.0007583682,0.001080856,0.0001776907,0.0002012625,0.0009082154,0.000360666,0.0006837946,0.003631234],"category_scores_gemma":[0.001219972,0.0002061068,0.001203595,0.0002546825,0.000338193,0.0006967215,0.0002951498,0.001783371,0.0006533854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007884556,"about_ca_system_score_gemma":0.001077518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008705454,"about_ca_topic_score_gemma":0.00283138,"domain_scores_codex":[0.9997001,0.0001672727,0.00001063241,0.00003915572,0.00002711399,0.00005576928],"domain_scores_gemma":[0.9995536,0.0001349907,0.00008627543,0.00003777234,0.00002568069,0.0001615318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7547075,0.004562592,0.005884178,0.001100066,0.003540718,0.0001489852,0.0000896421,0.002838546,0.01020481,0.0006791336,0.01601775,0.2002261],"study_design_scores_gemma":[0.8710048,0.06830535,0.03480414,0.0002100604,0.002707601,0.0002887752,0.00007139316,0.00242056,0.001964816,0.001694202,0.01648489,0.00004338415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9669328,0.01487911,0.0008256841,0.004543619,0.0005596718,0.0008000195,0.003248014,0.0001548345,0.00805633],"genre_scores_gemma":[0.9767328,0.006283127,0.001691503,0.002502183,0.0004467059,0.0009965847,0.004673788,0.00005925539,0.006614062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003631234,"threshold_uncertainty_score":0.01214767,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05743798171861608,"score_gpt":0.3983253528339085,"score_spread":0.3408873711152924,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}